ISAL 2023 | The importance of evaluating heterogeneity in AML and how this may impact MRD assessment
Jacqueline Cloos
• 20 Mar 2023
Jacqueline Cloos, PhD, Amsterdam UMC, Amsterdam, The Netherlands, briefly discusses the importance of investigating clonal evolution in acute myeloid leukemia (AML) to better understand how this may impact accurate measurable residual disease (MRD) assessment. This interview took place at the 18th International Symposium on Acute Leukemias (ISAL XVIII), held in Munich, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Disclosure (institute) received research funding from Takeda, DC-one, Genentech, Janssen, Novartis, Merus and royalties from Navigate and BD Biosciences.
